ThromboGenics reported a net loss of €51.1 million in 2014, compared with a net profit of €26.4 million in 2013, according to a press release.In addition, ThromboGenics reported decreases in total revenues, gross profit, and cash and investments in fiscal year 2014.
Adverse event rates low in AMD patients who take anti-VEGFs
Patients treated with anti-VEGFs for age-related macular degeneration had a low rate of adverse events that was comparable to the rate in the general population in Singapore, a study found.The retrospective population-based study included 1,182 patient…
TxCell to present at upcoming US and French investment conferences
Damian Marron, CEO, TxCell, will present at the Alliance for Regenerative Medicine’s 3rd Annual Regen Med Investor Day, New York, March 25, 2015. In addition, Damian Marron will also participate at the Portzamparc PEA-PME Forum, Paris, April 1, 2015.
Loyola ophthalmologist recommends specific foods and supplements for healthy vision
You may remember your mother telling you to eat your carrots; they are good for your eyes. Well, she was right. “Carrots are actually just one of the many foods, and supplements that contribute to good eye health,” says James McDonnell, MD, pediatric o…
Aerie completes enrollment in second phase 3 registration trial of Rhopressa
Aerie Pharmaceuticals completed enrollment in a second phase 3 registration trial of Rhopressa, according to a press release.Rocket 2 will measure efficacy over 3 months and safety over 1 year of Rhopressa, a once-daily eye drop that may lower IOP in p…
VIDEO: Speaker discusses the advantages of swept source OCT
At Retina 2015, SriniVas Sadda, MD, discusses the advantages of swept source OCT over existing commercial SD-OCT devices.